Cipher Pharmaceuticals DB:PHE Stok Raporu Şirket Finansalları + 3 Analistler
Cipher Pharmaceuticals Inc.
DB:PHE Stok Raporu
PHE Stoklara Genel Bakış Cipher Pharmaceuticals Inc. Kanada'da özel bir ilaç şirketi olarak faaliyet göstermektedir. Daha fazla detay
Ödüller Risk Analizi Tüm Risk Kontrollerini Gör Cipher Pharmaceuticals Inc. Rakipler Fiyat Geçmişi ve Performans
için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Cipher Pharmaceuticals Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı CA$8.55 52 Haftanın En Yüksek Seviyesi CA$13.00 52 Haftanın En Düşük Seviyesi CA$3.60 Beta 1.17 11 Aylık Değişim -23.66% 3 Aylık Değişim -10.00% 1 Yıllık Değişim 136.19% 33 Yıllık Değişim 466.23% 5 Yıllık Değişim 982.28% Halka arzdan bu yana değişim 223.86%
Son Haberler & Güncellemeler
Investor sentiment deteriorates as stock falls 17% Nov 14
Third quarter 2024 earnings released: EPS: US$0.011 (vs US$0.28 in 3Q 2023) Nov 10
New major risk - Earnings quality Nov 10
Cipher Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 07, 2024 Nov 04
Cipher Pharmaceuticals Inc. Appoints Hamed Ghanei as Chief Business Officer Oct 08
Investor sentiment improves as stock rises 15% Oct 04 Daha fazla güncelleme görün
Investor sentiment deteriorates as stock falls 17% Nov 14
Third quarter 2024 earnings released: EPS: US$0.011 (vs US$0.28 in 3Q 2023) Nov 10
New major risk - Earnings quality Nov 10
Cipher Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 07, 2024 Nov 04
Cipher Pharmaceuticals Inc. Appoints Hamed Ghanei as Chief Business Officer Oct 08
Investor sentiment improves as stock rises 15% Oct 04
Investor sentiment deteriorates as stock falls 21% Sep 13
Investor sentiment improves as stock rises 18% Aug 20 Cipher Pharmaceuticals Inc. Announces CFO Changes
Second quarter 2024 earnings released: EPS: US$0.12 (vs US$0.12 in 2Q 2023) Aug 09
Cipher Pharmaceuticals Inc. to Report Q2, 2024 Results on Aug 08, 2024 Aug 02
New major risk - Share price stability Aug 01
Investor sentiment improves as stock rises 16% Jul 30
First quarter 2024 earnings released: EPS: US$0.21 (vs US$0.10 in 1Q 2023) May 10
Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 14, 2024 Apr 09
Investor sentiment improves as stock rises 25% Mar 21
Full year 2023 earnings released: EPS: US$0.81 (vs US$1.05 in FY 2022) Mar 15
Cipher Pharmaceuticals Inc. to Report Q4, 2023 Results on Mar 14, 2024 Mar 09
Investor sentiment improves as stock rises 20% Feb 17
Investor sentiment improves as stock rises 16% Jan 06
Investor sentiment improves as stock rises 24% Nov 16
Third quarter 2023 earnings released: EPS: US$0.28 (vs US$0.11 in 3Q 2022) Nov 12
Cipher Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 09, 2023 Oct 28 Cipher Pharmaceuticals Inc. (TSX:CPH) announces an Equity Buyback for CAD 6 million worth of its shares. Sep 06
Second quarter 2023 earnings released: EPS: US$0.12 (vs US$0.085 in 2Q 2022) Aug 11
Cipher Pharmaceuticals Inc. to Report Q2, 2023 Results on Aug 10, 2023 Jul 29
Less than half of directors are independent Jun 02
First quarter 2023 earnings released: EPS: US$0.10 (vs US$0.083 in 1Q 2022) May 13
Cipher Pharmaceuticals Inc. to Report Q1, 2023 Results on May 11, 2023 May 05
Full year 2022 earnings released: EPS: US$1.05 (vs US$0.29 in FY 2021) Mar 17
Cipher Pharmaceuticals Inc. Declares Quarterly Dividend, Payable on or About February 28, 2023 Feb 14
Independent Director recently sold €56k worth of stock Dec 18
Third quarter 2022 earnings released: EPS: US$0.11 (vs US$0.03 in 3Q 2021) Nov 16
Third quarter 2022 earnings released: EPS: US$0.11 (vs US$0.03 in 3Q 2021) Nov 12
Cipher Pharmaceuticals Inc. to Report Q3, 2022 Results on Nov 10, 2022 Oct 27
Second quarter 2022 earnings released: EPS: US$0.08 (vs US$0.10 in 2Q 2021) Aug 13
Cipher Pharmaceuticals Inc. Announces Appointment of Bryan Jacobs as Chief Financial Officer Aug 12
Cipher Pharmaceuticals Inc. to Report Q2, 2022 Results on Aug 11, 2022 Aug 06
John Mull Decides Not to Stand for Re-Election as Director of Cipher Pharmaceuticals Inc Jun 23
First quarter 2022 earnings released: EPS: US$0.08 (vs US$0.05 in 1Q 2021) May 14 Cipher Pharmaceuticals Inc. to Report Q1, 2022 Results on May 12, 2022 May 10
Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 22, 2022 Apr 19
Investor sentiment improved over the past week Mar 24
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Mar 19
Investor sentiment improved over the past week Feb 09
Investor sentiment improved over the past week Dec 25
Third quarter 2021 earnings released: EPS US$0.03 (vs US$0.059 in 3Q 2020) Nov 12
Investor sentiment improved over the past week Sep 14
Investor sentiment improved over the past week Aug 19
Second quarter 2021 earnings released: EPS US$0.11 (vs US$0.015 in 2Q 2020) Aug 14
Investor sentiment improved over the past week Jun 08
First quarter 2021 earnings released: EPS US$0.05 (vs US$0.092 in 1Q 2020) May 16
Cipher Pharmaceuticals Inc. to Report Q4, 2020 Results on Mar 18, 2021 Mar 11
Cipher Pharmaceuticals Receives Arbitration Award on Trulance Jan 16
New 90-day high: €0.74 Jan 08
Third quarter 2020 earnings released: EPS US$0.06 Nov 14
Revenue beats expectations Nov 14
New 90-day low: €0.59 Nov 10
Cipher Pharmaceuticals Inc. to Report Q3, 2020 Results on Nov 12, 2020 Nov 05
New 90-day low: €0.64 Oct 21
Cipher Pharmaceuticals Inc. Approves the Appointment of Cathy Steiner as Director Oct 10
New 90-day low: €0.69 Sep 28
New 90-day low - €0.71 Aug 28
First half earnings released Aug 14
New 90-day high - €0.95 Aug 10
New 90-day high - €0.87 Jul 16 Hissedar Getirileri PHE DE Pharmaceuticals DE Pazar 7D -17.0% -3.1% -0.2% 1Y 136.2% -20.4% 7.8%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: PHE geçen yıl % -20.4 oranında getiri sağlayan German Pharmaceuticals sektörünü aştı.
Getiri vs Piyasa: PHE geçen yıl % 7.8 oranında getiri sağlayan German Piyasasını aştı.
Fiyat Oynaklığı Is PHE's price volatile compared to industry and market? PHE volatility PHE Average Weekly Movement 10.0% Pharmaceuticals Industry Average Movement 8.1% Market Average Movement 4.8% 10% most volatile stocks in DE Market 10.7% 10% least volatile stocks in DE Market 2.4%
İstikrarlı Hisse Senedi Fiyatı: PHE hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.
Zaman İçindeki Volatilite: PHE 'nin haftalık oynaklığı ( 10% ) geçen yıl boyunca sabit kaldı, ancak hala German hisselerinin %75'inden yüksek.
Şirket Hakkında Cipher Pharmaceuticals Inc. Kanada'da özel bir ilaç şirketi olarak faaliyet göstermektedir. Şiddetli nodüler ve/veya inflamatuar akne, akne konglobat ve rekalsitrant akne tedavisinde endike oral retinoid Epuris (isotretinoin); yüz, alın ve saçsız saçlı deride hafif palpe edilebilen ve/veya orta kalınlıkta hiperkeratotik aktinik keratoz (Grade I/II) tedavisinde endike topikal solüsyon Actikerall; impetigonun topikal tedavisi için Ozanex; Kadınlarda istenmeyen yüz tüylerinin büyümesini yavaşlatmak için topikal bir krem olan Vaniqa; yetişkinlerde orta ila orta derecede şiddetli ağrının yönetimi için bir opioid analjezik olan Durela; yetişkinlerde başlangıçtaki atriyal fibriallasyonun sinüs ritmine hızlı bir şekilde dönüştürülmesi için Brinavess; ve Akut Koroner Sendromlu hastalarda kullanılmak üzere geri dönüşümlü bir GP IIb/IIIa inhibitörü olan Aggrastat. Şirketin lisanslı ürünleri arasında şiddetli nodüler ve/veya inflamatuar akne, akne konglobat ve rekalsitrant akne tedavisinde endike bir oral retinoid olan Absorica yer almaktadır; Yetişkin hastalarda yüksek LDL-K, total-K, trigliseritler ve Apo B'yi azaltmak ve HDL-K'yi artırmak ve trigliseritleri azaltmak için diyete ek tedavi olarak endike olan Lipofen; ve yetişkinlerde orta ila orta derecede şiddetli kronik ağrının tedavisinde endike olan bir opioid agonisti olan Conzip.
Daha fazla göster Cipher Pharmaceuticals Inc. Temel Bilgiler Özeti Cipher Pharmaceuticals'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? PHE temel i̇stati̇sti̇kler Piyasa değeri €220.08m Kazançlar(TTM ) €15.04m Gelir(TTM ) €25.09m
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) PHE gelir tablosu (TTM ) Gelir US$26.46m Gelir Maliyeti US$5.09m Brüt Kâr US$21.38m Diğer Giderler US$5.52m Kazançlar US$15.86m
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
